World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 87 1193 1082 41 39 393 39766
Medicine 87 13421 12629 439 428 403 40011

Jonathan Cebon publications per year

The chart shows the history of publications by Jonathan Cebon between 1985 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Jonathan Cebon published across 41 years, from 1985 to 2025, averaging 12.6 papers a year. Output peaked at 101 publications in 2023. 24 of the 518 publications appeared in the last two years.

No. of publications
25 50 75 100
Bar chart. Horizontal axis: year, 1985 to 2025. Vertical axis: number of publications, 0 to 101. Peak 101 publications in 2023. 1985: 1 publication 1986: 0 publications 1987: 0 publications 1988: 2 publications 1989: 6 publications 1990: 8 publications 1991: 3 publications 1992: 4 publications 1993: 3 publications 1994: 10 publications 1995: 4 publications 1996: 3 publications 1997: 9 publications 1998: 10 publications 1999: 4 publications 2000: 14 publications 2001: 8 publications 2002: 6 publications 2003: 8 publications 2004: 14 publications 2005: 15 publications 2006: 11 publications 2007: 7 publications 2008: 11 publications 2009: 18 publications 2010: 15 publications 2011: 9 publications 2012: 15 publications 2013: 20 publications 2014: 20 publications 2015: 22 publications 2016: 25 publications 2017: 23 publications 2018: 15 publications 2019: 13 publications 2020: 23 publications 2021: 14 publications 2022: 0 publications 2023: 101 publications 2024: 8 publications 2025: 16 publications
1985 2025

518 publications in total across all disciplines

View publications per year as a table
Jonathan Cebon: publications per year, 1985 to 2025
Year Publications
1985 1
1986 0
1987 0
1988 2
1989 6
1990 8
1991 3
1992 4
1993 3
1994 10
1995 4
1996 3
1997 9
1998 10
1999 4
2000 14
2001 8
2002 6
2003 8
2004 14
2005 15
2006 11
2007 7
2008 11
2009 18
2010 15
2011 9
2012 15
2013 20
2014 20
2015 22
2016 25
2017 23
2018 15
2019 13
2020 23
2021 14
2022 0
2023 101
2024 8
2025 16
Total 518
Download as CSV

Jonathan Cebon publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jonathan Cebon sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 392–401 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 393 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62 393
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Jonathan Cebon D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jonathan Cebon sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 86–87 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 87 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102 87
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Jonathan Cebon is a researcher affiliated with La Trobe University in Australia. Their work primarily spans the fields of Medicine and Immunology and Microbiology, with a significant focus on Oncology, Immunology, Molecular Biology, Surgery, and Pulmonary and Respiratory Medicine.

Their main research topics include:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Vaccines and immunoinformatics approaches
  • Ovarian cancer diagnosis and treatment

Jonathan Cebon has contributed to several journals with multiple publications in key venues such as Clinical Cancer Research, JAMA Oncology, Journal for ImmunoTherapy of Cancer, Cell Death Discovery, and Annals of Oncology.

Frequent co-authors collaborating with them include:

  • Andreas Behren
  • Matteo S. Carlino
  • Oliver Klein
  • Damien Kee
  • Jodie Palmer

Notable recent papers authored by Jonathan Cebon encompass the following:

  • Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells, 2020, Science
  • Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers, 2020, JAMA Oncology
  • Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers, 2020, Clinical Cancer Research
  • Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma, 2021, Nature Immunology
  • Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma, 2020, Science Advances

Best Publications

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

    Mark R Middleton;J J Grob;N Aaronson;G Fierlbeck

  • Whole-genome landscapes of major melanoma subtypes

    Nicholas K. Hayward;Nicholas K. Hayward;James S. Wilmott;Nicola Waddell;Nicola Waddell;Peter A. Johansson

  • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    Antoni Ribas;Reinhard Dummer;Igor Puzanov;Ari VanderWalde

  • Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology

    Edouard Stanley;Graham J. Lieschke;Graham J. Lieschke;Dianne Grail;Donald Metcalf

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

    Marian L Burr;Marian L Burr;Marian L Burr;Christina E Sparbier;Yih-Chih Chan;James C Williamson

  • Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells

    Thomas Luft;Ken C Pang;Elisabeth Thomas;Paul J Hertzog

  • Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

    Ian D. Davis;Weisan Chen;Heather Jackson;Phillip Parente;Phillip Parente

  • Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets

    Thomas Luft;Michael Jefford;Petra Luetjens;Tracey Toy

  • Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells.

    Marc Rigau;Marc Rigau;Simone Ostrouska;Thomas S Fulford;Darryl N Johnson

  • Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib

    Georgina Long;Jeffrey s Weber;Jeffrey R Infante;Kevin B Kim

  • Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial

    Darryl W. Maher;Graham J. Lieschke;Michael Green;James Bishop

  • Tumor antigen expression in melanoma varies according to antigen and stage

    Catherine Barrow;Judy Browning;Duncan MacGregor;Ian D. Davis

  • Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer

    Russell L. Basser;John E.J. Rasko;Kerrie Clarke;Jonathan Cebon

  • Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

    Mario Sznol;Pier Francesco Ferrucci;David Hogg;Michael B Atkins

  • Large Scale Identification of Human Hepatocellular Carcinoma-Associated Antigens by Autoantibodies

    Yu Wang;Ke-Jun Han;Xue-Wen Pang;Hilary A. Vaughan

  • Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

    Georgina V. Long;Georgina V. Long;Victoria Atkinson;Victoria Atkinson;Jonathan S. Cebon;Michael B. Jameson

Frequent Co-Authors

Ian D. Davis
Ian D. Davis Monash University
Weisan Chen
Weisan Chen La Trobe University
Eugene Maraskovsky
Eugene Maraskovsky CSL (United Kingdom)
Georgina V. Long
Georgina V. Long University of Sydney
Richard F. Kefford
Richard F. Kefford Macquarie University
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
Matteo S. Carlino
Matteo S. Carlino University of Sydney
Lloyd J. Old
Lloyd J. Old Ludwig Cancer Research
Alexander Dobrovic
Alexander Dobrovic University of Melbourne
Andrew M. Scott
Andrew M. Scott La Trobe University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology opens diverse career pathways, particularly in healthcare and research. For those interested in advanced clinical roles, pursuing an acute care NP certification can be a valuable step. This certification allows nurse practitioners to specialize in managing patients with complex conditions, complementing immunology expertise.

Nursing professionals looking to accelerate their careers can explore an accelerated NP program. These programs offer a fast-track route to becoming a nurse practitioner, combining clinical knowledge with specialized immunological skills.

For individuals without a nursing background, online accelerated nursing programs for non nurses provide an accessible pathway into nursing. These programs help bridge the gap from other fields into nursing careers, laying the groundwork for advanced studies in immunology-related healthcare roles.

Additionally, those seeking easy entry into nursing can consider absn programs with high acceptance rates. These accelerated Bachelor of Science in Nursing programs offer flexible options to start a nursing career sooner, which can pair well with further immunology specialization.

Best Scientists Citing Jonathan Cebon

Trending Scientists

Recently Published Articles